Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2026-03-18 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于向特定对象发行A股股票涉及关联交易事项暨与特定对象签署附条件生效的股份认购协议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the issuance of A shares to a specific party, including the signing of a conditional share subscription agreement, pricing, approval procedures, governance changes, and related party transaction disclosures. It involves a capital raising event through a private placement to a specific investor, which is a financing activity. The document is not a full financial report, audit report, or earnings release, nor is it a simple announcement of a report publication. It is not about board changes alone, nor is it a voting result or dividend notice. The content focuses on the capital issuance and related transaction details, fitting the Capital/Financing Update category.
2026-03-18 Chinese
关于公司股东签署《共同投资暨一致行动协议》及公司签署《附条件生效的股份认购协议》暨控股股东、实际控制人拟发生变更的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a significant change in the company's controlling shareholder and actual controller due to a planned issuance of shares to a specific investor. It includes information about the share subscription agreement, the joint investment and concerted action agreement, changes in shareholding percentages, board composition changes, and conditions for the issuance. The document is not a financial report, earnings release, or audit report. It is a formal announcement about a capital/financing event involving issuance of new shares and change in control. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (8304 characters) and detailed content support this classification with high confidence.
2026-03-18 Chinese
2026年度向特定对象发行A股股票预案
Capital/Financing Update Classification · 100% confidence The document is a detailed plan and proposal for a specific issuance of A shares to a particular investor (腾云新沃) by 云南沃森生物技术股份有限公司 in 2026. It includes comprehensive information about the issuance scheme, background, purpose, pricing, number of shares, use of proceeds, impact on control, shareholder structure, and regulatory approvals required. The document is titled as a "2026年度向特定对象发行A股股票预案" which translates to "2026 Annual Proposal for Private Placement of A Shares." This is a capital raising activity involving issuance of new shares to a specific party, with detailed terms and conditions, pricing, and regulatory compliance. It is not an announcement of results, not a transcript, not a report on earnings or annual performance, nor a governance or management change announcement. It is a detailed capital/financing update document describing a private placement of shares. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the full proposal, not just an announcement or summary.
2026-03-18 Chinese
关于召开2026年第二次临时股东会的通知
AGM Information Classification · 100% confidence The document is a detailed notice for the convening of the 2026 second extraordinary general meeting (临时股东会) of Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting time, location, voting procedures, proposal details, and registration instructions. The content focuses on the announcement and organization of a shareholders' meeting, including proposals to be voted on, but does not contain financial statements or results. The document is not a report itself but a formal meeting notice and related procedural information. Therefore, it fits the category of AGM Information (AGM-R). The document length is over 5,000 characters and contains detailed meeting information, not just a brief announcement, confirming it is the meeting notice itself rather than a report publication announcement or regulatory filing.
2026-03-18 Chinese
关于无需编制前次募集资金使用情况报告的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company regarding the non-requirement to prepare a previous fundraising usage report. It references regulatory guidelines and states that no fundraising has occurred in the last five years, so no report or audit is needed. The document is brief (502 characters) and serves as a formal notice rather than a detailed report or financial statement. It does not contain financial data or detailed analysis, nor is it a certification letter. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit other categories.
2026-03-18 Chinese
2026年度向特定对象发行股票方案论证分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Yunnan Watson Biotechnology Co., Ltd. regarding a 2026 private placement of shares to specific investors. It discusses the background, purpose, legal compliance, pricing, issuance method, fairness, financial impact, and commitments related to the issuance of new A shares. The content includes extensive analysis of the issuance plan, regulatory compliance references, financial assumptions, and shareholder impact. This is a comprehensive issuance plan and analysis report related to capital raising through a private placement of shares, which fits the category of Capital/Financing Update filings. It is not an announcement of a report publication, nor a general regulatory filing, nor a full annual or interim report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2026-03-18 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.